Protocol to request
CRISPRi cyclophosphamide hypersensitivity screen
Research article
A curative combination cancer therapy achieves high fractional cell killing through low cross-resistance and drug additivity
Adam C Palmer et al.
DOI: 10.7554/eLife.50036